AC IMMUNE SA SF-02 Cash Flow-to-Debt Ratio
AC IMMUNE SA SF-02 cash flow-to-debt ratio. AC IMMUNE SA SF-02 (IMR) has a Cash Flow-to-Debt Ratio of -0.15x as of December 2025, meaning its operating cash flow of €-16.51 Million could theoretically repay 0% of its total liabilities (€109.37 Million) in one year. Check IMR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of AC IMMUNE SA SF-02 (2021–2025)
Cash flow-to-debt ratio of AC IMMUNE SA SF-02 from 2021 to 2025. Historical debt coverage capacity for AC IMMUNE SA SF-02 across 5 annual periods. Check AC IMMUNE SA SF-02 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
AC IMMUNE SA SF-02 Cash Flow-to-Debt Ratio by Year (2021–2025)
AC IMMUNE SA SF-02 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for AC IMMUNE SA SF-02. For the full cash flow conversion analysis, see IMR cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.63x | €-69.26 Million | €109.37 Million | ▼ -214.1% |
| 2024 | 0.55x | €65.84 Million | €118.64 Million | ▲ +120.4% |
| 2023 | -2.72x | €-60.41 Million | €22.17 Million | ▲ +37.2% |
| 2022 | -4.34x | €-73.57 Million | €16.95 Million | ▼ -94.7% |
| 2021 | -2.23x | €-65.69 Million | €29.46 Million | — |